Disclosure of summary of significant accounting policies [Line Items]

No definition available.

Name:	alvo_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix:	alvo_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Non-current contract assets materialize period.

+ References

No definition available.

+ Details

Name:	alvo_NoncurrentContractAssetsMaterializePeriod
Namespace Prefix:	alvo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Non-current contract liabilities revenue recognition period.

+ References

No definition available.

+ Details

Name:	alvo_NoncurrentContractLiabilitiesRevenueRecognitionPeriod
Namespace Prefix:	alvo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront And Milestone Consideration, Payments

+ References

No definition available.

+ Details

Name:	alvo_UpfrontAndMilestoneConsiderationPayments
Namespace Prefix:	alvo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of current contract assets. [Refer: Contract assets]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 105
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_CurrentContractAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of current contract liabilities. [Refer: Contract liabilities]

+ References

+ Details

Name:	ifrs-full_CurrentContractLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of non-current contract assets. [Refer: Contract assets]

+ References

+ Details

Name:	ifrs-full_NoncurrentContractAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of non-current contract liabilities. [Refer: Contract liabilities]

+ References

+ Details

Name:	ifrs-full_NoncurrentContractLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 113
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard
-URIDate 2025-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [domain]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 120
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_a&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 108
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 108
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_a&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	ifrs-full_ProductsAndServicesAxis=alvo_LicenseRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	alvo_CounterpartyGroupNameAxis=alvo_TevaPharmaceuticalIndustriesLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	alvo_CounterpartyGroupNameAxis=alvo_STADAArzneimittelAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	alvo_CounterpartyGroupNameAxis=alvo_AdvanzPharmaHoldingsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	alvo_CounterpartyGroupNameAxis=alvo_AlvogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MaturityAxis=alvo_NotLaterThanFiveYearsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
Revenue - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Disclosure of summary of significant accounting policies [Line Items]
Revenue	$ 211,637	$ 306,004
Non-current contract assets	165,007		$ 122,934
Current contract assets	68,673		64,440
Non-current contract liabilities	4,177		5,500
Current contract liabilities	18,190		$ 30,364
License revenue (point in time revenue recognition) \| Goods or services transferred at point in time
Disclosure of summary of significant accounting policies [Line Items]
Revenue	39,750	$ 0
Teva Pharmaceutical Industries Ltd
Disclosure of summary of significant accounting policies [Line Items]
Upfront and milestone consideration, payment	150,000
STADA Arzneimittel AG
Disclosure of summary of significant accounting policies [Line Items]
Upfront and milestone consideration, payment	105,600
Advanz Pharma Holdings
Disclosure of summary of significant accounting policies [Line Items]
Upfront and milestone consideration, payment	227,900
Alvogen
Disclosure of summary of significant accounting policies [Line Items]
Upfront and milestone consideration, payment	15,000
Not later than five years \| Performance obligations satisfied over time
Disclosure of summary of significant accounting policies [Line Items]
Transaction price allocated to remaining performance obligations	$ 343,800
Bottom of range
Disclosure of summary of significant accounting policies [Line Items]
Non-current contract assets materialize period	2 years
Noncurrent contract liabilities revenue recognition period	2 years
Top of range
Disclosure of summary of significant accounting policies [Line Items]
Non-current contract assets materialize period	4 years
Noncurrent contract liabilities revenue recognition period	3 years